COX-2-IN-31 (compound 7b) is an orally active dual inhibitor targeting COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM), and also inhibits transmembrane hCA IX (Ki=48.9 nM) and hCA XII (Ki=5.8 nM), demonstrating anti-inflammatory and analgesic activity [1].

COX-2:60 nM, COX-1:12.5 μM

In the carbonic anhydrase inhibition assay, COX-2-IN-31 (compound 7b) effectively inhibited hCA IX and XII with Kᵢ values within the nanomolar range (48.9 nM and 5.8 nM) [1].

COX-2-IN-31 (compound 7b), administered orally at 10 mg/kg, demonstrated analgesic activity by significantly reducing writhing episodes in mice and decreasing paw edema height in carrageenan-induced rat paw edema tests while exhibiting gastric safety in albino male rats at this dose level [1].